CelExel Clinical Innovations — Bellflower, California

CelExel Clinical Innovations is a clinical research site located in Bellflower, California, United States 90706.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

CelExel Clinical Innovations has participated in 1 clinical trials.

Therapeutic areas: Schizophrenia.

Sponsors: LB Pharmaceuticals Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Bellflower

Browse all research sites in California · View every site in Bellflower

• Bel Tooren Villa Convalescent Hospital
• Kaiser Foundation Hospital
• Kaiser Permanente-Bellflower
• CiTrials
• Clinical Innovations
• Research Site
• Clinical Innovations, Inc. dba CITrials
• Clinical Research Site
• Southern California Permanente Medical Group
• Pfizer Investigational Site
• Coast Clinical Research, LLC
• CITrials - Bellflower

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for CelExel Clinical Innovations?

CelExel Clinical Innovations has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has CelExel Clinical Innovations conducted?

CelExel Clinical Innovations has 1 clinical trials on record. Their work covers Schizophrenia.

Is CelExel Clinical Innovations accredited by Crixeo Clinical Trials?

CelExel Clinical Innovations has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about CelExel Clinical Innovations?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.